Alemtuzumab treatment in Denmark: A national study based on the Danish Multiple Sclerosis Registry

Asta Theodorsdottir, Birgit Debrabant, Melinda Magyari, Matthias Kant, Peter V. Rasmussen, Carl Fredrik Malmberg, Iver A. Norberg, Victoria Hansen, Danny Bech, Mathias F. Schmidt, Karen Schreiber, Jette L. Frederiksen, Finn Sellebjerg, Zsolt Illes*

*Kontaktforfatter for dette arbejde

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Abstrakt

Objective: To investigate clinical outcomes in a real-world setting in the complete population-based cohort of alemtuzumab-treated MS patients in Denmark. Methods: Data were retrieved from The Danish Multiple Sclerosis Registry between 2009 and 2019. Demographic and disease-specific patient parameters related to treatment history, efficacy, and safety outcomes were assessed at baseline and during follow-up visits. Results: A total of 209 patients (78% female) started treatment with alemtuzumab during the study period with 3.1 ± 1.4 years follow-up. After 2 years, 75% of patients were relapse-free compared to 48% the year before alemtuzumab (p < 0.001). The annual number of relapses was reduced by 69% in year 4 compared with the year prior alemtuzumab. More active disease before alemtuzumab increased the annual hazard rate for relapse (HR: 2.88, p < 0.001). The Expanded Disability Status Scale (EDSS) score remained stable or improved in 81% of patients after 2 years. The need for an additional treatment course was associated with higher number of relapses in the year before alemtuzumab (odds ratio (OR) = 1.95, p = 0.001). Conclusion: In a country with primarily escalation strategy, relapse rate reduction was maintained for 5 years, and EDSS stabilized/improved in majority of patients. Higher relapse rate 1 year before alemtuzumab increased the odds for additional courses. Novel serious AEs were not observed.

OriginalsprogEngelsk
TidsskriftMultiple Sclerosis Journal
ISSN1352-4585
DOI
StatusE-pub ahead of print - 29. mar. 2021

Bibliografisk note

Publisher Copyright:
© The Author(s), 2021.

Fingeraftryk Dyk ned i forskningsemnerne om 'Alemtuzumab treatment in Denmark: A national study based on the Danish Multiple Sclerosis Registry'. Sammen danner de et unikt fingeraftryk.

Citationsformater